Cargando…

HIV pre-exposure prophylaxis and diagnoses of sexually transmitted infections – observational data from German checkpoints, 01/2019–08/2021

BACKGROUND: The impact of starting HIV pre-exposure prophylaxis (PrEP) on diagnoses of sexually transmitted infections (STI) remains unclear. We used data from German HIV/STI Checkpoints collected from 01/2019 to 08/2021 to determine the impact of PrEP use on syphilis, gonorrhoea and chlamydia diagn...

Descripción completa

Detalles Bibliográficos
Autores principales: Marcus, Ulrich, Schink, Susanne B., Weber, Christoph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10082478/
https://www.ncbi.nlm.nih.gov/pubmed/37029369
http://dx.doi.org/10.1186/s12889-023-15570-6
_version_ 1785021321737928704
author Marcus, Ulrich
Schink, Susanne B.
Weber, Christoph
author_facet Marcus, Ulrich
Schink, Susanne B.
Weber, Christoph
author_sort Marcus, Ulrich
collection PubMed
description BACKGROUND: The impact of starting HIV pre-exposure prophylaxis (PrEP) on diagnoses of sexually transmitted infections (STI) remains unclear. We used data from German HIV/STI Checkpoints collected from 01/2019 to 08/2021 to determine the impact of PrEP use on syphilis, gonorrhoea and chlamydia diagnoses. METHODS: We used self-reported data on demographics, sexual behaviour, testing and PrEP use, as well as lab-confirmed diagnoses from visits to HIV/STI Checkpoints in Germany. PrEP use was categorized as (1) never used; (2) intention to use; (3) former use; (4) current on-demand use; (5) daily use. In multivariate regression analyses (MRA) with gonorrhoea, chlamydia, and syphilis diagnoses as outcomes, we controlled for age, number of sexual partners, number of condomless anal intercourse (CAI) partners in the last six months, and testing recency. RESULTS: For the analysis, we included 9,219 visits for gonorrhoea and chlamydia testing and 11,199 visits for syphilis testing conducted at checkpoints from 01/2019 to 08/2021. MRA identified age (aOR 0.98; 95%CI 0.97–0.99), number of sexual partners in the past six months (aOR 4.90; 95%CI 2.53–9.52 for 11 + partners), and use of chemsex substances (aOR 1.62; 95%CI 1.32-2.00) as risk factors for gonorrhoea, while age (aOR 0.99; 95%CI 0.98-1.00), number of CAI partners (aOR 3.19; 95%CI 2.32–4.41 for 5 + partners), partner sorting (aOR 1.30; 95%CI 1.09–1.54), and use of chemsex substances (aOR 1.29; 95%CI 1.05–1.59) were risk factors for chlamydia infections. For syphilis, the number of CAI partners (aOR 3.19; 95%CI 1.60–6.34 for 5 + partners) was found to be the only significant risk factor. There was a strong association between PrEP use and the number of sexual partners (≤ 5 vs.>5: aOR 3.58; 95%CI 2.15–5.97 for daily PrEP use), the number of CAI partners in the past six months (≤ 1 vs.>1: aOR 3.70; 95%CI 2.15–6.37 for daily PrEP use), and the number of STI tests performed (suggesting higher testing frequency). Both outcomes were also related to partner sorting, chemsex, and selling sex. CONCLUSIONS: Checkpoint visits reporting current PrEP use or intention to start PrEP correlated with eligibility criteria for PrEP, i.e. high partner numbers, inconsistent condom use during anal intercourse, and use of chemsex drugs. Use of HIV-specific prevention methods such as HIV serosorting, PrEP sorting, and viral load sorting was reported more frequently. (Daily) PrEP use was an independent risk factor for a chlamydia diagnosis only. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12889-023-15570-6.
format Online
Article
Text
id pubmed-10082478
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-100824782023-04-09 HIV pre-exposure prophylaxis and diagnoses of sexually transmitted infections – observational data from German checkpoints, 01/2019–08/2021 Marcus, Ulrich Schink, Susanne B. Weber, Christoph BMC Public Health Research BACKGROUND: The impact of starting HIV pre-exposure prophylaxis (PrEP) on diagnoses of sexually transmitted infections (STI) remains unclear. We used data from German HIV/STI Checkpoints collected from 01/2019 to 08/2021 to determine the impact of PrEP use on syphilis, gonorrhoea and chlamydia diagnoses. METHODS: We used self-reported data on demographics, sexual behaviour, testing and PrEP use, as well as lab-confirmed diagnoses from visits to HIV/STI Checkpoints in Germany. PrEP use was categorized as (1) never used; (2) intention to use; (3) former use; (4) current on-demand use; (5) daily use. In multivariate regression analyses (MRA) with gonorrhoea, chlamydia, and syphilis diagnoses as outcomes, we controlled for age, number of sexual partners, number of condomless anal intercourse (CAI) partners in the last six months, and testing recency. RESULTS: For the analysis, we included 9,219 visits for gonorrhoea and chlamydia testing and 11,199 visits for syphilis testing conducted at checkpoints from 01/2019 to 08/2021. MRA identified age (aOR 0.98; 95%CI 0.97–0.99), number of sexual partners in the past six months (aOR 4.90; 95%CI 2.53–9.52 for 11 + partners), and use of chemsex substances (aOR 1.62; 95%CI 1.32-2.00) as risk factors for gonorrhoea, while age (aOR 0.99; 95%CI 0.98-1.00), number of CAI partners (aOR 3.19; 95%CI 2.32–4.41 for 5 + partners), partner sorting (aOR 1.30; 95%CI 1.09–1.54), and use of chemsex substances (aOR 1.29; 95%CI 1.05–1.59) were risk factors for chlamydia infections. For syphilis, the number of CAI partners (aOR 3.19; 95%CI 1.60–6.34 for 5 + partners) was found to be the only significant risk factor. There was a strong association between PrEP use and the number of sexual partners (≤ 5 vs.>5: aOR 3.58; 95%CI 2.15–5.97 for daily PrEP use), the number of CAI partners in the past six months (≤ 1 vs.>1: aOR 3.70; 95%CI 2.15–6.37 for daily PrEP use), and the number of STI tests performed (suggesting higher testing frequency). Both outcomes were also related to partner sorting, chemsex, and selling sex. CONCLUSIONS: Checkpoint visits reporting current PrEP use or intention to start PrEP correlated with eligibility criteria for PrEP, i.e. high partner numbers, inconsistent condom use during anal intercourse, and use of chemsex drugs. Use of HIV-specific prevention methods such as HIV serosorting, PrEP sorting, and viral load sorting was reported more frequently. (Daily) PrEP use was an independent risk factor for a chlamydia diagnosis only. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12889-023-15570-6. BioMed Central 2023-04-07 /pmc/articles/PMC10082478/ /pubmed/37029369 http://dx.doi.org/10.1186/s12889-023-15570-6 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Marcus, Ulrich
Schink, Susanne B.
Weber, Christoph
HIV pre-exposure prophylaxis and diagnoses of sexually transmitted infections – observational data from German checkpoints, 01/2019–08/2021
title HIV pre-exposure prophylaxis and diagnoses of sexually transmitted infections – observational data from German checkpoints, 01/2019–08/2021
title_full HIV pre-exposure prophylaxis and diagnoses of sexually transmitted infections – observational data from German checkpoints, 01/2019–08/2021
title_fullStr HIV pre-exposure prophylaxis and diagnoses of sexually transmitted infections – observational data from German checkpoints, 01/2019–08/2021
title_full_unstemmed HIV pre-exposure prophylaxis and diagnoses of sexually transmitted infections – observational data from German checkpoints, 01/2019–08/2021
title_short HIV pre-exposure prophylaxis and diagnoses of sexually transmitted infections – observational data from German checkpoints, 01/2019–08/2021
title_sort hiv pre-exposure prophylaxis and diagnoses of sexually transmitted infections – observational data from german checkpoints, 01/2019–08/2021
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10082478/
https://www.ncbi.nlm.nih.gov/pubmed/37029369
http://dx.doi.org/10.1186/s12889-023-15570-6
work_keys_str_mv AT marcusulrich hivpreexposureprophylaxisanddiagnosesofsexuallytransmittedinfectionsobservationaldatafromgermancheckpoints012019082021
AT schinksusanneb hivpreexposureprophylaxisanddiagnosesofsexuallytransmittedinfectionsobservationaldatafromgermancheckpoints012019082021
AT weberchristoph hivpreexposureprophylaxisanddiagnosesofsexuallytransmittedinfectionsobservationaldatafromgermancheckpoints012019082021